JP2008508864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508864A5 JP2008508864A5 JP2007518205A JP2007518205A JP2008508864A5 JP 2008508864 A5 JP2008508864 A5 JP 2008508864A5 JP 2007518205 A JP2007518205 A JP 2007518205A JP 2007518205 A JP2007518205 A JP 2007518205A JP 2008508864 A5 JP2008508864 A5 JP 2008508864A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- seq
- human
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000002227 Interferon Type I Human genes 0.000 claims 5
- 108010014726 Interferon Type I Proteins 0.000 claims 5
- 230000005856 abnormality Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 4
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims 3
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 2
- 238000001516 cell proliferation assay Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 241000699660 Mus musculus Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58174704P | 2004-06-21 | 2004-06-21 | |
| US60/581,747 | 2004-06-21 | ||
| PCT/US2005/021951 WO2006002177A2 (en) | 2004-06-21 | 2005-06-20 | Interferon alpha receptor 1 antibodies and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012217849A Division JP5899540B2 (ja) | 2004-06-21 | 2012-09-28 | インターフェロンアルファレセプター１抗体及びその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008508864A JP2008508864A (ja) | 2008-03-27 |
| JP2008508864A5 true JP2008508864A5 (cg-RX-API-DMAC7.html) | 2008-08-07 |
| JP5160887B2 JP5160887B2 (ja) | 2013-03-13 |
Family
ID=35782299
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518205A Expired - Lifetime JP5160887B2 (ja) | 2004-06-21 | 2005-06-20 | インターフェロンアルファレセプター１抗体及びその使用法 |
| JP2012217849A Expired - Lifetime JP5899540B2 (ja) | 2004-06-21 | 2012-09-28 | インターフェロンアルファレセプター１抗体及びその使用法 |
| JP2015135415A Pending JP2015172088A (ja) | 2004-06-21 | 2015-07-06 | インターフェロンアルファレセプター１抗体及びその使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012217849A Expired - Lifetime JP5899540B2 (ja) | 2004-06-21 | 2012-09-28 | インターフェロンアルファレセプター１抗体及びその使用法 |
| JP2015135415A Pending JP2015172088A (ja) | 2004-06-21 | 2015-07-06 | インターフェロンアルファレセプター１抗体及びその使用法 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US7662381B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1781705B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5160887B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20150041193A (cg-RX-API-DMAC7.html) |
| CN (3) | CN102603894B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005258077C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2570823C (cg-RX-API-DMAC7.html) |
| CY (2) | CY1115875T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2662390T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2526194T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE035082T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2662390T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007000023A (cg-RX-API-DMAC7.html) |
| PL (2) | PL2662390T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT2662390T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2600884C2 (cg-RX-API-DMAC7.html) |
| SI (2) | SI1781705T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006002177A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100409897C (zh) * | 2003-04-23 | 2008-08-13 | 梅达雷克斯公司 | 1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途 |
| KR20150041193A (ko) * | 2004-06-21 | 2015-04-15 | 메다렉스, 엘.엘.시. | 인터페론 알파 수용체 1 항체 및 그의 용도 |
| WO2006054748A1 (ja) * | 2004-11-22 | 2006-05-26 | Ginkgo Biomedical Research Institute Co., Ltd. | 腎炎の治療剤 |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| CN101678100A (zh) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗系统性红斑狼疮的方法 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| WO2009061818A1 (en) | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
| EP2250279B1 (en) | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| AU2008359583B2 (en) * | 2008-07-16 | 2012-04-05 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
| PE20141432A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| CN101580546B (zh) * | 2009-06-04 | 2011-09-14 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗人干扰素α抗体及其应用 |
| RU2012112802A (ru) | 2009-09-03 | 2013-10-10 | МЕДИММЬЮН, ЭлЭлСи | Диагностика интерферона типа 1 |
| KR102320059B1 (ko) * | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| WO2014134223A1 (en) * | 2013-02-26 | 2014-09-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2906526C (en) | 2013-03-15 | 2022-12-06 | Ellen Chi | Interferon alpha and omega antibody antagonists |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015061526A1 (en) * | 2013-10-25 | 2015-04-30 | Medimmune, Llc | Antibody purification |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| RU2580301C1 (ru) * | 2015-04-21 | 2016-04-10 | Людмила Николаевна Хон | Способ лечения системной красной волчанки человека |
| US10329258B2 (en) | 2015-04-30 | 2019-06-25 | University Of Washington | CGAS in systemic lupus erythematosus (SLE) |
| HUE061985T2 (hu) * | 2015-08-19 | 2023-09-28 | Astrazeneca Ab | Stabil IFNAR1-elleni készítmény |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| US11136399B2 (en) | 2016-07-14 | 2021-10-05 | Institute Of Biophysics, Chinese Academy Of Sciences | Type I interferon receptor antibody and use thereof |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| WO2018172957A1 (en) | 2017-03-21 | 2018-09-27 | Austrianni Gmbh | Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases |
| KR20200130350A (ko) | 2018-03-05 | 2020-11-18 | 얀센 파마슈티카 엔.브이. | 항-phf-타우 항체 및 이의 용도 |
| AU2019276776B2 (en) * | 2018-06-01 | 2025-12-11 | ILC Therapeutics Limited | Compositions and methods relating to the treatment of diseases |
| SG11202101946YA (en) * | 2018-09-18 | 2021-04-29 | I Mab Biopharma Hangzhou Co Ltd | Anti-ifnar1 antibodies for treating autoimmune diseases |
| CN115925950A (zh) * | 2019-01-31 | 2023-04-07 | 广东旋玉健康生物科技有限公司 | 新型抗ifnar1抗体 |
| KR20210131354A (ko) | 2019-02-15 | 2021-11-02 | 아스트라제네카 아베 | I형 인터페론-매개 장애 |
| EP4494712A3 (en) | 2019-11-11 | 2025-03-26 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| JP2023522928A (ja) * | 2020-04-20 | 2023-06-01 | ファロン ファーマシューティカルズ オサケ ユキチュア | インターロイキン阻害剤と組み合わせたｃｌｅｖｅｒ－１阻害による疾患の治療 |
| BR112022023438A2 (pt) | 2020-05-29 | 2022-12-20 | Astrazeneca Ab | Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| IL302871A (en) | 2020-11-18 | 2023-07-01 | Astrazeneca Ab | Steroid sparing |
| HUE063562T2 (hu) * | 2021-04-23 | 2024-01-28 | Astrazeneca Ab | Anti-IFNAR1 adagolási rend szubkután injekcióhoz |
| AU2022261422A1 (en) * | 2021-04-23 | 2023-11-30 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
| PL4192882T3 (pl) | 2021-04-23 | 2025-04-28 | Astrazeneca Ab | Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem |
| US20250002591A1 (en) | 2021-05-12 | 2025-01-02 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| CN113621063A (zh) * | 2021-08-02 | 2021-11-09 | 江苏荃信生物医药有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 |
| TW202340245A (zh) | 2021-07-27 | 2023-10-16 | 瑞典商阿斯特捷利康公司 | 狼瘡之治療 |
| CA3233069A1 (en) | 2021-10-04 | 2023-04-13 | Astrazeneca Ab | Treatment of lupus |
| CN119585314A (zh) | 2022-08-29 | 2025-03-07 | 江苏恒瑞医药股份有限公司 | 包含taci多肽的融合蛋白及其用途 |
| WO2024046305A1 (zh) | 2022-08-29 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 免疫调节剂的筛选和制备方法 |
| CN120344259A (zh) * | 2022-10-13 | 2025-07-18 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| CN121127499A (zh) | 2023-05-19 | 2025-12-12 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5516515A (en) | 1986-02-05 | 1996-05-14 | Interferon Sciences, Inc. | Separation of alpha interferon receptor proteins and antibodies therefor |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL88377A (en) | 1988-11-14 | 1996-09-12 | Yeda Res & Dev | Cloning and expression of a protein which modulates cellular response to type I interferon |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5889151A (en) | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| FR2653445B1 (fr) | 1989-10-20 | 1994-07-29 | Centre Nat Rech Scient | Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante. |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| DE69214656T2 (de) | 1991-08-30 | 1997-03-13 | Genentech Inc | Therapeutisches verfahren zur behandlung von iddm |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5821078A (en) | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| ATE173630T1 (de) | 1992-12-29 | 1998-12-15 | Genentech Inc | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| CA2171955A1 (en) | 1993-09-17 | 1995-03-23 | Michael G. Tovey | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995013808A1 (en) | 1993-11-15 | 1995-05-26 | Cell Therapeutics, Inc. | Method for selectively inhibiting il-2 signal transduction |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US7285526B2 (en) | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
| DE69919327D1 (de) | 1998-01-30 | 2009-11-26 | Allertein Therapeutics Llc | Prognostische allergie- oder entzündungstest |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| US6329159B1 (en) | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| GB0001712D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
| GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| IT1321086B1 (it) | 2000-11-24 | 2003-12-30 | Cselt Centro Studi Lab Telecom | Sistema e metodo per individuare la posizione di apparecchiaturemobili |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| ES2363761T3 (es) | 2001-01-09 | 2011-08-16 | Baylor Research Institute | Procedimientos para el tratamiento de enfermedades autoinmunitarias en un sujeto y en ensayos de diagnóstico in vitro. |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| WO2004090390A1 (ja) | 2003-04-02 | 2004-10-21 | Kabushiki Kaisha Riken | シールリング |
| EP1631590B1 (en) | 2003-04-23 | 2011-07-27 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
| CN100409897C (zh) | 2003-04-23 | 2008-08-13 | 梅达雷克斯公司 | 1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途 |
| PL2418220T3 (pl) | 2003-12-10 | 2017-12-29 | E. R. Squibb & Sons, L.L.C. | Przeciwciała przeciwko interferonowi alfa i ich zastosowania |
| KR20150041193A (ko) | 2004-06-21 | 2015-04-15 | 메다렉스, 엘.엘.시. | 인터페론 알파 수용체 1 항체 및 그의 용도 |
| EP2250279B1 (en) * | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| KR102320059B1 (ko) * | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| HUE063562T2 (hu) * | 2021-04-23 | 2024-01-28 | Astrazeneca Ab | Anti-IFNAR1 adagolási rend szubkután injekcióhoz |
-
2005
- 2005-06-20 KR KR1020157008445A patent/KR20150041193A/ko not_active Withdrawn
- 2005-06-20 RU RU2010138567/10A patent/RU2600884C2/ru active
- 2005-06-20 KR KR1020147002166A patent/KR101541658B1/ko not_active Expired - Lifetime
- 2005-06-20 CN CN201210053959.2A patent/CN102603894B/zh not_active Expired - Lifetime
- 2005-06-20 KR KR1020077001467A patent/KR101335079B1/ko not_active Expired - Lifetime
- 2005-06-20 PL PL13162333T patent/PL2662390T3/pl unknown
- 2005-06-20 ES ES05787743.3T patent/ES2526194T3/es not_active Expired - Lifetime
- 2005-06-20 CA CA2570823A patent/CA2570823C/en not_active Expired - Lifetime
- 2005-06-20 SI SI200531919T patent/SI1781705T1/sl unknown
- 2005-06-20 LT LTEP13162333.2T patent/LT2662390T/lt unknown
- 2005-06-20 DK DK13162333.2T patent/DK2662390T3/da active
- 2005-06-20 KR KR1020127032569A patent/KR20130012258A/ko not_active Ceased
- 2005-06-20 MX MX2007000023A patent/MX2007000023A/es active IP Right Grant
- 2005-06-20 WO PCT/US2005/021951 patent/WO2006002177A2/en not_active Ceased
- 2005-06-20 RU RU2007102079/10A patent/RU2412202C2/ru active
- 2005-06-20 AU AU2005258077A patent/AU2005258077C1/en active Active
- 2005-06-20 PT PT131623332T patent/PT2662390T/pt unknown
- 2005-06-20 EP EP05787743.3A patent/EP1781705B1/en not_active Expired - Lifetime
- 2005-06-20 US US11/157,494 patent/US7662381B2/en not_active Expired - Lifetime
- 2005-06-20 PT PT57877433T patent/PT1781705E/pt unknown
- 2005-06-20 JP JP2007518205A patent/JP5160887B2/ja not_active Expired - Lifetime
- 2005-06-20 EP EP13162333.2A patent/EP2662390B1/en not_active Expired - Lifetime
- 2005-06-20 DK DK05787743.3T patent/DK1781705T3/en active
- 2005-06-20 CN CN2005800250345A patent/CN101001878B/zh not_active Expired - Lifetime
- 2005-06-20 ES ES13162333.2T patent/ES2643237T3/es not_active Expired - Lifetime
- 2005-06-20 HU HUE13162333A patent/HUE035082T2/en unknown
- 2005-06-20 PL PL05787743T patent/PL1781705T3/pl unknown
- 2005-06-20 SI SI200532169T patent/SI2662390T1/sl unknown
- 2005-06-20 CN CN2012102755280A patent/CN102863532A/zh active Pending
-
2010
- 2010-02-12 US US12/704,948 patent/US8460668B2/en active Active
-
2012
- 2012-09-28 JP JP2012217849A patent/JP5899540B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-09 US US13/890,494 patent/US9453077B2/en active Active
-
2014
- 2014-12-23 CY CY20141101085T patent/CY1115875T1/el unknown
-
2015
- 2015-07-06 JP JP2015135415A patent/JP2015172088A/ja active Pending
-
2016
- 2016-09-09 US US15/261,386 patent/US10385133B2/en not_active Expired - Lifetime
-
2017
- 2017-10-17 CY CY20171101083T patent/CY1119512T1/el unknown
-
2019
- 2019-07-03 US US16/503,196 patent/US11072664B2/en not_active Expired - Lifetime
-
2021
- 2021-06-22 US US17/354,610 patent/US20210395375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508864A5 (cg-RX-API-DMAC7.html) | ||
| RU2007102079A (ru) | Антитела рецептора интерферона альфа и их применение | |
| JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| Schmid et al. | Advances in antibody engineering for rheumatic diseases | |
| RU2766094C2 (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| JP2010511388A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500005A5 (cg-RX-API-DMAC7.html) | ||
| JP2012501670A5 (cg-RX-API-DMAC7.html) | ||
| JP2009502171A5 (cg-RX-API-DMAC7.html) | ||
| WO2014206107A1 (zh) | 抗pd-1抗体及其应用 | |
| RU2009128064A (ru) | Антитела к cd44 | |
| JP2007514419A5 (cg-RX-API-DMAC7.html) | ||
| JP2015519375A5 (cg-RX-API-DMAC7.html) | ||
| JP2011509245A5 (cg-RX-API-DMAC7.html) | ||
| CN109022465A (zh) | 多肽构建体及其用途 | |
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| JP2015504896A5 (cg-RX-API-DMAC7.html) | ||
| JP2012100667A5 (cg-RX-API-DMAC7.html) | ||
| JP2006089494A (ja) | Ｉ型インターフェロンに対する中和活性を有するインターフェロン受容体に対するモノクローナル抗体 | |
| JPH06500229A (ja) | 擬人化ｃｄｒ移植抗ｉｃａｍ―１抗体、その生産方法及びその使用 | |
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| CN117279950B (zh) | 一种靶向il-18bp的抗体及其应用 | |
| Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
| Samuel et al. | Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development | |
| CN110114370A (zh) | 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段 |